Monoclonal Antibody Regeneron

Regeneron Gets CHMP Backing of Linvoseltamab

Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug

Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).

MarketWatch · 3d

Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma

Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have shown disease progression on the last therapy.

Business Insider · 3d

Regeneron announces EMA CHMP adopted positive opinion on linvoseltamab

Pharmaceuticals announced that the European Medicines Agency’s, EMA, Committee for Medicinal Products for Human Use, CHMP, has

Seeking Alpha on MSN · 3d

Regeneron's linvoseltamab gets positive EU regulatory opinion

Regeneron Pharmaceuticals (NASDAQ:REGN) said the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended conditional marketing authorization of its drug linvoseltamab for the treatment of adults with relapsed and refractory multiple myeloma.

MarketBeat on MSN4d

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

(NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: ...

Pharmaceutical Technology13d

FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid

Regeneron and Sanofi have collaborated on Dupixent since ... among other secondary endpoints. Dupixent, a fully human ...

Nasdaq3d

Regeneron's Linvoseltamab Receives Positive CHMP Opinion For Treating Relapsed/Refractory MM

(RTTNews) - Regeneron Pharmaceuticals ... an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and have shown disease progression on the last treatment. The positive opinion follows ...

Regeneron Pharmaceuticals Unusual Options Activity For February 25

The general mood among these heavyweight investors is divided, with 62% leaning bullish and 18% bearish. Among these notable ...

Linvoseltamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Multiple Myeloma

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results